Biosynex
Biosynex
ALBIO
EURONEXT
1.62
EUR
0.00%
About
Biosynex SA is a France-based company that specializes in the research, development and manufacture of in-vitro diagnostic kits aimed at health professionals. The Company’s products are used by biological and analytical services laboratories, obstetric units and emergency units, as well as in medical resource-limited settings.
Biosynex SA specializes in four fields: tropical diseases, emergency markers, infectious diseases and autoimmunity. The Company’s products include Amnioquick (Obstetrics); Immunoquick Malaria Falciparum and Immunoquick Malaria +4 (Parasitology); Immunoquick Elifa HSV IGG, Immunoquick Elifa EBV G and Immunoquick Mono (Virology); Immunoquick Filtration CELIAC IgA and Immunoquick TG (Autoimmunology); and Immunoquick Tetanus (Bacteriology).
It operates through Fumouze Diagnostics and SR2B..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 32.9K |
| Three Month Average Volume | 412.5K |
| High Low | |
| Fifty-Two Week High | 10.9 EUR |
| Fifty-Two Week Low | 2.83 EUR |
| Fifty-Two Week High Date | 06 Sep 2023 |
| Fifty-Two Week Low Date | 03 Jul 2024 |
| Price and Volume | |
| Current Price | 5.06 EUR |
| Beta | -3 |
| Relative Price Change | |
| Four Week Relative Price Change | 23.52% |
| Thirteen Week Relative Price Change | 32.32% |
| Twenty-Six Week Relative Price Change | -14.25% |
| Fifty-Two Week Relative Price Change | -54.53% |
| Year-to-Date Relative Price Change | -40.22% |
| Price Change | |
| One Day Price Change | -2.32% |
| Thirteen Week Price Change | 26.50% |
| Twenty-Six Week Price Change | -17.59% |
| Five Day Price Change | -0.78% |
| Fifty-Two Week Price Change | -52.35% |
| Year-to-Date Price Change | -39.40% |
| Month-to-Date Price Change | -2.32% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 11.91894 EUR |
| Book Value Per Share (Most Recent Quarter) | 11.91894 EUR |
| Tangible Book Value Per Share (Last Fiscal Year) | -0.65723 EUR |
| Tangible Book Value Per Share (Most Recent Quarter) | -0.65723 EUR |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -2.65261 EUR |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 8.90263 EUR |
| Revenue Per Share (Trailing Twelve Months) | 9.09753 EUR |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 EUR |
| Dividend Per Share (Trailing Twelve Months) | 0 EUR |
| Dividend Per Share (5 Year) | -99999.99 EUR |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -3.55443 EUR |
| Excluding Extraordinary Items (Trailing Twelve Months) | -3.63755 EUR |
| Normalized (Last Fiscal Year) | -3.577 EUR |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -3.55443 EUR |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -3.63755 EUR |
| Including Extraordinary Items (Last Fiscal Year) | -3.55443 EUR |
| Including Extraordinary Items (Trailing Twelve Months) | -3.63755 EUR |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 2.5051 EUR |
| Cash Per Share (Most Recent Quarter) | 2.5051 EUR |
| Cash Flow Per Share (Last Fiscal Year) | -2.42391 EUR |
| Cash Flow Per Share (Trailing Twelve Months) | -2.47697 EUR |
| Free Cash Flow Per Share (Trailing Twelve Months) | -4.81383 EUR |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -53 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -41.05% |
| Pretax Margin (Last Fiscal Year) | -41.05% |
| Pretax Margin (5 Year) | 20.52% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 52.84% |
| Gross Margin (Trailing Twelve Months) | 52.84% |
| Gross Margin (5 Year) | 51.92% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -37.78% |
| Operating Margin (Trailing Twelve Months) | -37.78% |
| Operating Margin (5 Year) | 21.28% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -38.30% |
| Net Profit Margin (Trailing Twelve Months) | -38.30% |
| Net Profit Margin (5 Year) | 14.61% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 30.06% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -7.40% |
| Revenue Growth (3 Year) | 24.40% |
| Revenue Change (Trailing Twelve Months) | -52.70% |
| Revenue Per Share Growth | 21.11% |
| Revenue Growth (5 Year) | -15.46% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | 66.22% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -15.43% |
| EPS Change (Trailing Twelve Months) | -342.60% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | 39.6M |
| Net Debt (Last Fiscal Year) | 39.6M |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 1 |
| Price to Sales (Trailing Twelve Months) | 1 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 28 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 2 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 0 |
| Price to Book (Most Recent Quarter) | 0 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 48 |
| Long Term Debt to Equity (Most Recent Quarter) | 48 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 1 |
| Quick Ratio (Most Recent Quarter) | 1 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 2 |
| Current Ratio (Most Recent Quarter) | 2 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -49,198,000 |
| Free Cash Flow (Trailing Twelve Months) | -49,198,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -18 |
| Net Interest Coverage (Trailing Twelve Months) | -28 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 53 |
| Total Debt to Equity (Most Recent Quarter) | 53 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -14.18% |
| Return on Assets (Trailing Twelve Months) | -14.18% |
| Return on Assets (5 Year) | 14.90% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -25.87% |
| Return on Equity (Trailing Twelve Months) | -25.87% |
| Return on Equity (5 Year) | 22.81% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -17.51% |
| Return on Investment (Trailing Twelve Months) | -17.51% |
| Return on Investment (5 Year) | 19.41% |